Endocannabinoid system alterations in Alzheimer's disease: A mini-review
National Health Service, Department of Mental Health, Termoli, Italy.
Review Article
World Journal of Advanced Research and Reviews, 2024, 22(03), 1374–1380
Article DOI: 10.30574/wjarr.2024.22.3.1814
Publication history:
Received on 18 May 2024; revised on 17 June 2024; accepted on 19 June 2024
Abstract:
Alzheimer's disease is the most common form of progressively disabling degenerative dementia with onset predominantly in pre-senile age. There are many risk factors for developing Alzheimer's disease, some of which are modifiable. The etiopathological aspects are characterized by the presence of extracellular deposits of Beta-Amyloid and by the hyperphosphorylation of the tau protein associated with cytoskeletal microtubules. The Endocannabinoid System is a complex molecular/biological system that participates in numerous physiological pathways of the organism. From the data in the scientific literature, alterations in the components of the Endocannabinoid System in Alzheimer's disease emerge, even if some data are conflicting. However, further research is necessary to further confirm the published data.
Keywords:
Endocannabinoid System; Alzheimer’s disease; Etiopathogenesis; ECS alterations
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0